Skip to main content
Log in

The Authors’ Reply

  • Correspondence
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Golomb BA, Kopersli S, Evans M. Statins and muscle adverse events: a complementary perspective [letter]. Drug Saf 2010; 33(9): 803

    Article  PubMed  Google Scholar 

  2. Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33: 171–87

    Article  PubMed  CAS  Google Scholar 

  3. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781–90

    Article  PubMed  CAS  Google Scholar 

  4. Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008; 337: a2286

    Article  PubMed  Google Scholar 

  5. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8: 373–418

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giannoglou, G.D., Koskinas, K.C. & Chatzizisis, Y.S. The Authors’ Reply. Drug-Safety 33, 803–804 (2010). https://doi.org/10.2165/11538830-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11538830-000000000-00000

Keywords

Navigation